NICE to rule on influenza flu drug zanamivir
BMJ 1999; 319 doi: https://doi.org/10.1136/bmj.319.7215.937 (Published 09 October 1999) Cite this as: BMJ 1999;319:937- Gavin Yamey
- BMJ
The British pharmaceutical industry will start to move out of Britain if the government makes the environment antagonistic to its interests, Sir Richard Sykes, chairman of GlaxoWellcome, predicted on Monday.
Sir Richard's comments, on BBC Radio 4's Today programme, came after it was reported that the National Institute for Clinical Excellence (NICE) was about to recommend to the health secretary, Frank Dobson, that GlaxoWellcome's new influenza drug zanamivir (Relenza), should not be available on the NHS.
Sir Richard said that his company was not threatening to pull out of Britain, but he warned: “If [the government] continues to …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £164 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£30 / $37 / €33 (excludes VAT)
You can download a PDF version for your personal record.